Douglas Thomson

CEO & Co-founder, Pneumagen Limited

Douglas is CEO and a co-founder at Pneumagen, a clinical phase anti-infective company. Founded in April 2016, Pneumagen is developing first-in-class products for the prevention and treatment of infectious disease.

Amongst other roles, he was previously at SingVax, in Singapore, as CEO, and Microscience Ltd as Business Development Director. Douglas currently sits on the board of Omideon, a St. Andrews based biotech company focused on the development of novel treatments for cancer. He is a Venture Partner with the KAMRA fund, which is focused on infectious disease.